American Society of Retina Specialists

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key interviews from the American Society of Retina Specialists (ASRS) 42nd Annual Meeting.

Pre-dose IOP outcomes in eyes with DME receiving aflibercept 8 mg or 2 mg were comparable through Week 48 of the Phase 2/3 PHOTON trial.

A post hoc analysis of PHOTON showed the utility of aflibercept 8 mg in patients with DME, irrespective of baseline visual acuity.

A recap of the 5 most popular topics related to gene therapy in ophthalmology coming from the 42nd American Society of Retina Specialists meeting.

Hesitancy with anti-VEGF biosimilars was identified in a survey among both ophthalmologists and patients with nAMD in Canada.

Across 40 clinical scenarios, ChatGPT did not provide a comprehensive response in 50% of clinical questions with nearly 30% hallucinated sources.

Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.

Intravitreal dosing of sozinibercept up to 2 mg in combination with ranibizumab or aflibercept was well tolerated and supported ≥Q8W dosing intervals.

A database analysis linked semaglutide use to notable reductions in the rates of diabetic macular edema and vitreous hemorrhage in diabetic retinopathy.

Presented at ASRS 2024, late-breaking RHONE-X data shows more than 90% of patients experienced the absence of DME after four years of faricimab.

The FDA accepted Genentech’s supplemental BLA for Susvimo, based on the one-year results from the Phase III Pagoda and Pavilion studies.

Eyes with GA that developed MNV in the GATHER trials experienced a slower growth rate with avaincaptad pegol than with sham treatment.

Patients treated with PDS with ranibizumab refilled every nine months maintained vision improvements and experienced consistent safety over two years.

New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.

New data from the TEASE-3 trial presented at the ASRS meeting shows gildeuretinol acetate may blunt disease progression in early-stage Stargardt disease patients.

Over 2 years, the Port Delivery System demonstrated continued efficacy with fixed refill-exchange procedures every 24 weeks in the Phase 3 Pagoda trial.

Interim results from the PRISM population extension cohort found that 4D-150 was well tolerated and reduced the mean annualized anti-VEGF injection rate.

At 24 weeks, the oral therapy was well-tolerated and the safety profile remained in line with previous brepocitinib studies and the pharmacological class.

One-year 1/2 data examines the safety and efficacy of OCU400 gene therapy for the treatment of retinitis pigmentosa.

New data from RHONE-X at ASRS suggest over 90% of DME patients treated with faricimab (Vabysmo) were DME-free at 4 years, with nearly 80% on 3-4 month dosing intervals.

An ASRS 2024 study found no significant difference in post-injection endophthalmitis rates between using nonsterile gloves and not using gloves for anti-VEGF injections.

Topline Phase 2b/3 results show high- and low-dose MCO-010 treatment improved BCVA compared to control through 100 weeks.

A single Ixo-vec injection showed up to a 95% reduction in annualized anti-VEGF injections, according to first-time 26-week results from the Phase 2 LUNA study.

Pegcetacoplan for 36 months led to fewer absolute scotomatous points on microperimetry than delayed treatment, suggesting its efficacy in preserving vision.

RGX-314 produced by the NAVXpress platform process showed a similar clinical profile to the adherent cell culture process in this Phase 2 pharmacodynamic study.

Phase 2 data from the ARCHER study shows a protective effect of ANX007 on visual acuity and anatomical measures in the central macula in patients with GA.

OTX-TKI remained generally well-tolerated in patients with moderately severe to severe NPDR across 48 weeks of the Phase 1 trial.

Katherine Talcott, MD describes a posthoc analysis of the GATHER trials showing how imaging biomarkers of photoreceptor structure predict GA growth.

Veeral Sheth, MD describes an assessment of the need for supplemental injection use after EYP-1901 for wet AMD.

The PRISM trial's 24-week data show 4D-150 reduced anti-VEGF injection rates by 89% in wet AMD, with 77% of patients injection-free at 24 weeks.